-
Gene Expression Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Lymph Node-Positive Early Breast Cancer: A Systematic Review
Sep 9, 2025, 16:22 PM -
An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Sep 9, 2025, 16:22 PM -
Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis
Sep 9, 2025, 16:22 PM -
An Update on the Evolving Use of Artificial intelligence and Machine Learning (AI/ML) in Systematic Literature Reviews (SLRs)
Sep 9, 2025, 16:22 PM -
Maximizing Profits Through Pricing: Opportunities in Portugal's Pharma Sector
Sep 9, 2025, 16:22 PM -
KRAS Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Trends in Testing Patterns and Targeted Treatment Use Across Europe Between 2018 and 2024
Sep 9, 2025, 16:22 PM -
Strategies for More Cost-Effective HrHPV Screening: A Simulation Study of Pooled Testing Based on Real-World Data in Low- and Middle-Income Countries
Sep 9, 2025, 16:22 PM -
Markov Model-Based Cost-Effectiveness Evaluation of ROSA® vs. Manual Total Knee Arthroplasty: Sweden Payer Perspective
Sep 9, 2025, 16:22 PM -
Reassessing NICE's Highly Specialized Technologies (HST) Criteria: A Retrospective Review of Borderline and Approved Appraisals Under the Revised Framework
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Artificial Intelligence Interventions for Musculoskeletal Disorders: Systematic Review
Sep 9, 2025, 16:22 PM -
HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals
Sep 9, 2025, 16:22 PM -
Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)
Sep 9, 2025, 16:22 PM -
Evaluating the Role of Disease-Specific Patient-Reported Outcomes in HTA Submissions for Rare Conditions: A Comparative Case Study of Narcolepsy and Phenylketonuria
Sep 9, 2025, 16:22 PM -
A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia
Sep 9, 2025, 16:22 PM -
Budgetary Impact of Generalized Pustular Psoriasis (GPP) in the Brazilian Private Healthcare System: A Real-World Data Analysis
Sep 9, 2025, 16:22 PM -
Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments
Sep 9, 2025, 16:22 PM -
Comparing Risk of Bias Assessment Requirements Between the EU JCA and European HTA Agencies
Sep 9, 2025, 16:22 PM -
Using Machine Learning to Enable Timely Postpartum Care by Reliably Detecting Deliveries
Sep 9, 2025, 16:22 PM
